Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis

Journal of the Neurological Sciences
Lenka NovakovaJan Lycke

Abstract

Natalizumab therapy reduces inflammation and degeneration of the CNS in relapsing-remitting multiple sclerosis (RRMS). In cerebrospinal fluid (CSF) the concentration of 24S-hydroxycholesterol (24OHC) reflect neurodegeneration, whereas 27-hydroxycholesterol (27OHC) is dependent on the integrity of the blood-brain barrier (BBB). To measure the impact from natalizumab treatment on 24OHC and 27OHC concentrations in serum and CSF of RRMS. In serum and CSF obtained from 31 patients before and following 12 months of natalizumab treatment, 24OHC and 27OHC were analyzed by isotope-dilution mass spectrometry. Natalizumab treatment reduced CSF-24OHC concentrations (p=0.002), CSF-27OHC concentrations (p=0.01) and serum-24OHC concentrations (p=0.029). There was no significant effect of the treatment on serum-27OHC concentrations. Serum concentrations of 24OHC correlated with Symbol Digit Modalities Test scores before (r=0.5, p=0.007) and after natalizumab treatment (r=0.403, p=0.033). We showed for the first time that natalizumab treatment of RRMS reduced the concentrations of 24- and 27OHC in CSF, indicating reduced neurodegeneration and improved integrity of the BBB, respectively. Our results imply a role for serum 24OHC as a biomarker of...Continue Reading

References

Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·D LütjohannI Björkhem
Jan 29, 1998·The New England Journal of Medicine·B D TrappL Bö
Apr 4, 1998·Journal of Neurology, Neurosurgery, and Psychiatry·J N LyckeL E Rosengren
Jan 5, 2002·Journal of Psychiatric Research·A PapassotiropoulosR Heun
Oct 24, 2003·Pharmacopsychiatry·D Lütjohann, K von Bergmann
Apr 6, 2004·Clinical Chemistry and Laboratory Medicine : CCLM·Valerio LeoniIngemar Björkhem
Sep 6, 2005·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·Laura K SheridanRobert A Zucker
Sep 8, 2005·Clinical Neurology and Neurosurgery·Virginija Danylaité KarrenbauerThomas Masterman
Mar 3, 2006·The New England Journal of Medicine·Chris H PolmanUNKNOWN AFFIRM Investigators
May 16, 2007·Journal of Neurology·Peter Scherer
Jun 22, 2007·The New England Journal of Medicine·Richard M Ransohoff
Feb 10, 2009·Scandinavian Journal of Clinical and Laboratory Investigation·Valerio Leoni
Mar 3, 2009·Molecular Aspects of Medicine·Ingemar BjörkhemSteve Meaney
Jul 21, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·N PutzkiV Limmroth
Mar 10, 2011·Annals of Neurology·Chris H PolmanJerry S Wolinsky
Mar 17, 2011·Neuroscience Letters·V LeoniS Di Donato
Apr 2, 2013·Biochemical Pharmacology·Valerio Leoni, Claudio Caccia
May 25, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Markus AxelssonAnders Svenningsson
Aug 21, 2013·Multiple Sclerosis : Clinical and Laboratory Research·C van de KraatsC E Teunissen
Sep 11, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Judith M SonderBernard M J Uitdehaag

❮ Previous
Next ❯

Citations

Oct 22, 2016·Biochimica Et Biophysica Acta·Miguel MoutinhoElsa Rodrigues
Dec 20, 2017·Metabolic Brain Disease·Marcello MocciaVincenzo Brescia Morra
Mar 11, 2018·Journal of Neuroinflammation·Valentin MutembereziGiulio G Muccioli
May 23, 2019·Neurodegenerative Disease Management·Dejan JakimovskiRobert Zivadinov
Apr 15, 2016·Current Opinion in Neurology·Manuel ComabellaXavier Montalban
Sep 25, 2019·International Journal of Molecular Sciences·Donovan DucCaroline Pot
Sep 25, 2020·Journal of Clinical Medicine·Remsha AfzalClaire E McCoy
Oct 30, 2020·Journal of Neurochemistry·Alejandro O Sodero
Mar 9, 2021·The Journal of Steroid Biochemistry and Molecular Biology·Anne VejuxGérard Lizard
Jul 27, 2021·Frontiers in Aging Neuroscience·Irina A Pikuleva, Nathalie Cartier
Jul 25, 2021·International Journal of Molecular Sciences·Maria PodbielskaAnna Pokryszko-Dragan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier & Cytokines

Some cytokines are able to cross the blood brain barrier through transport systems and enter the cerebrospinal fluid and interstitial fluid spaces. Here is the latest research on cytokines crossing the blood brain barrier and how this can affect tissues within the CNS.

Related Papers

Clinical Chemistry and Laboratory Medicine : CCLM
Valerio LeoniIngemar Björkhem
The Cochrane Database of Systematic Reviews
Eugenio PucciIan Galea
The New England Journal of Medicine
Richard B Tenser
© 2021 Meta ULC. All rights reserved